

**SenseBioTek**  
HEALTHCARE

**BODY VOLATOLOME  
FOR DISEASE DETECTION**

**Nabil Moumane, MD**  
CEO & Founder

[an.moumane@sensebiotek.com](mailto:an.moumane@sensebiotek.com) — +33 7 88 11 58 70


<https://sensebiotek.com/>

<https://www.linkedin.com/company/sensebiotek-health-care/>



# Volatolome


Body odor



*Volatile organic compounds*

Metabolites

Skin



Blood, faeces,  
urine, breath...


Pathology :

- Diabetes
- Epilepsy
- **Covid-19**
- **Cancer**




Metabolic activity

Cell



# Is this something new?

## Ancient Greek and Roman medicine




Hippocrate



Galien




## Contemporary medicine




Trimethylamine



Diabetic  
ketoacidosis



Typhoid fever



Early 20th century



# Evidence

Every disease has unique scent

Mitra A, et al. The Human Skin Volatolome: A Systematic Review of Untargeted Mass Spectrometry Analysis. *Metabolites*. 2022 Sep 1;12(9):824.

01



**Disease metabolic  
process**

02



**Volatile Organic  
Compounds  
(VOCs)**

03



**Unique chemical  
fingerprint**

# Evidence






## Every disease has unique scent

**Nano**  
**R**esearch  
2022, 15(9): 8185–8213

ISSN 1998-0124 CN 11-5974/O4  
<https://doi.org/10.1007/s12274-022-4459-3>


### Volatolomics in healthcare and its advanced detection technology

Wenwen Hu<sup>1,§</sup>, Weiwei Wu<sup>2,§</sup>, Yingying Jian<sup>2,§</sup>, Hossam Haick<sup>3</sup>, Guangjian Zhang<sup>4</sup>, Yun Qian<sup>5</sup> (✉),  
Miaomiao Yuan<sup>6</sup> (✉), and Mingshui Yao<sup>7,8</sup> (✉)



# Evidence


## Every disease has unique scent



999  
études

29  
études  
éligibles


935  
sujets





# Evidence

## Every disease has unique scent




999  
études

29  
études  
éligibles

935  
sujets



Workflow	Analytical Step	Considerations
Experimental design	Define intended population	Patient selection
		Separate into training and independent validation cohorts
Sample preparation		Define the anatomical location of skin sampling
	Pre-sampling	Avoid personal care products at the location of sampling for a minimum of 24 h
		Consider patient medication and use of xenobiotics
	Skin VOC collection and storage	Direct contact vs. non-contact methods
		Choice of sampling material (cotton/PDMS/SPME)
MS analysis		Sampling time
		Sources of contamination
	Sampling technique	Sample storage (direct analysis or storage at -80 freezer)
		Consider the use of pre-concentration headspace step or direct injection
	Analytical platform	Use of internal standards in patch
Data Analysis		QCs (spiking with internal standards to monitor and correct analytical variability)
	MS data collection	Online or offline platforms
	Data pre-processing	Optimisation of MS parameters
		Run order (randomisation) and batch effects
	Statistical analysis	Data deconvolution, scaling, peak alignment
		Removal of irreproducible, contaminant compounds
		Descriptive statistics
		Univariate analysis
		Multivariate analysis (e.g., PCA, PLS-DA, OPLS-DA)
		Prediction model (e.g., ROC analysis)
	Biological interpretation	Metabolic pathways (KEGG, HMDB)



**SenseBioTek**  
HEALTHCARE

**SkinVOCs®**

1<sup>st</sup> Body Odor  
Sampling Device






# Our story

## From Canine Detection to Electronic Nose



# Roadmap to MVP

Medical Device with AI-powered Nanosensors



# Development of sampling device


## Sampling System Requirements



Sample duration < 1 hour




Samples can be taken from different parts of the body





# Development of sampling device

## Sampling System Requirements



# Development of sampling device

## Prototyping steps



COVID-19 Study

1<sup>st</sup> 3D printed Prototypes

1<sup>st</sup> Metal Prototypes

Post-study user feedback  
and improvements

Engineering Design

# SkinVOCs®

## Body Odor Sampling Device



01



02




03






# Methodology : Analytical flow and sampling

## Analytical flow



## Sampling



### - More powerful than 1D methods


- ↑ Nb of VOCs identified
- ↑ Confidence of peaks identification
- ↓ Limit of detection of VOCs

### - Required collaboration with expert

- Pr. Vial, ESPCI

*Less than 5 experts and 10 apparatus in France*


# Body odor spectra



**Great! We're seeing things!**  
**...But what exactly do we see?**



?




?



?





# Body odor mapping



Sampling in **4 different body areas**:  
armpit, upper back, forearm, groin



- Identification of area dependant or independant components within body odor



- Number of detected compound per sampled body area

Area	Armpit	Forearm	Upper back	Groin
Mean	885 ± 159	497 ± 34	655 ± 130	548 ± 58



High density of **sweat glands**  
Possibility of **maceration**  
**VOCs** with bacterial activity origin



**VOCs** with shampoo origin




# Use-case I : Cosmetic persistence




70 peaks attributed to cosmetics



64 molecules = non persistent cosmetics




6 molecules = persistent cosmetics




# Use-case II : Bacterial activity



15 peaks attributed to bacterial activity



2,3-Butanedione



# Use-case III : environmental exposure



Samples taken from an individual from Monday to Friday

**ChromaTile**


to identify significantly different compounds over the course of the week

Tuesday




Wednesday


Apparition of chlorine compounds



2,6-Dichloroacetophenone



Benzaldehyde, 2,4-dichloro-





# POC I : COVID-19 VOCs biomarkers

## AIM

- Investigating the connection between viruses and the body volatilome
- Identifying potential biomarkers
- Elucidate potential sources of inconsistency and external bias in biomarker findings

## METHODOLOGY

- 40 Covid + / 12 Covid -
- Armpits samples
- Powersorbs sorbent phase
- TD-GCxGC/ToFMS analysis
- chemometrics (F-ratio, volcano plot)

**24 compounds significantly different  
in Covid + and Covid -**

**12 linked to cosmetics**

### **5 biomarkers**

Assessed with ROC curves

*2-ethylhexanoic acid*

AUC 92.1%

Covid + = 16.4 ng vs Covid - = 6.5 ng


**7 linked to environment  
(hospital, air pollution)**

# SkinVOCs®

**The 1<sup>st</sup> innovative method to collect skin odor molecules**



Chromatography analysis




**SenseBioTek**  
HEALTHCARE

**SenseNose**  
Electronique Nose




Electronic nose based on the end-to-end integration of  
a carbon nanotube-based chemistor array


Chemistor



Interdigitated  
electrodes




Carbon nanotube with  
chemically-sensitive coating






# Concept : Details


- Chemistor array




- Functional probes




- Electronic and signal transduction




Real-time data display



# Bench POC : Gas detection






- 1- GAS SENSOR
- 2- PRESSURE SENSOR
- 3- TEMPERATURE AND HUMIDITY SENSOR
- 4- GAS INLET AND OUTLET





# Bench POC : Dynamic response

Gas : Acetone



Gas : 2-ethyl hexanoic acid



UNIQUE  
RESPONSE  
PATTERN



# Major Scientific Results

## Body Volatolome Study for COVID-19



- Deep evaluation of environmental and cosmetic effects
- 2-ethylhexanoic acid **biomarker** found and quantified in Covid(+) samples at **16.4 ng**



## Use of cosmetics and volatolome

- Evaluation of cosmetic persistence on skin
- Assessing deodorant performance by analyzing bacterial VOCs

## Nanosensors detection



- Picogram LOD as a major result (**< 1ng**)
- Different responses of the different sensors to different gas

\* Boudard et al. Volatilome Study Strategy for COVID-19 Biomarker Identification Considering Exogenous Parameters. Separations 2024, 11, 336



# Solution to speed up diagnosis

## Screening Medical Device

**Non Invasive, Easy to use, Accessible**

“Electronic Nose” that detects the smell of cancer  
before symptoms appear

01

**SkinVOCs®**  
(15 to 20 ‘)



02

**SenseNose**  
(Immediate results)



# Screening Medical device for Skin Cancers

Dedicated to General Practitioners

Multi-sensor central module



Single-use consumables  
(Subscription)



For General Practitioners

With SenseNose

VISIT + SCREENING FEES

**Reimbursed**  
by Social Security  
& Health insurance providers

# Competition

the only solution that detects symptoms before they appear

— COST

— EASY TO USE

— NON-INVASIVE

— EARLY DETECTION

— INSTANT RESULTS

— RELIABILITY

— MUTILCANCER

Derm.AI



Dermatoscope



SenseNose



Accessible



**Convenient**



Noninvasive



**Pre-symptomatic**



Quick



Reliable



**Scalable**

# The Team

## LEADERSHIP



**Nabil Moumane, (MD)**  
Founder & CEO

Health Physics Engineer,  
+15 years experience in the  
biomedical industry



**Nathalie Gagey (PhD, HDR)**  
Chief Technology Officer  
(CTO)

+15 years experience in Physics  
and Analytical Chemistry



**Sarah ELIRAKI (MD)**  
Chief Medico-Marketing  
Office (CSO)

+15 years experience in  
dermatology and immunology



**Boutaina Benkirane**  
Chief HR Officer (CHRO)

+15 years experience in  
business management



**Lambert Trenoras (PhD)**  
Chief Business Dev Officer  
(CBDO)

Robotic Engineer  
+15 years experience in  
MedTech

## OPERATIONS



**Kleidisa Rrushka**  
Chemical Engineer  
(employee-PhD)



**Emilie Duval**  
Engineer ESPCI-  
MINES



**Charlène Beyaz**  
Tech. Lab



**Q2 2025**  
Data  
Scientists

## ADVISORS



**Otmane Hajji**  
Finance Expert  
Engineer Centrale  
Paris



**Alice Matheron**  
Health Economics  
Expert Pharmacist



Medical Device  
International  
Business Dev



KOL In Oncology



# Scientific committee



**Pr Jean-Luc Perrot**  
Dermatology-Oncology  
CHU de St Etienne



**Dr Didier Thiebaut**  
Research Director,  
LSABM ESPCI Paris PSL,  
CNRS



**Dr Jérôme VIAL**  
Associate Professor,  
LSABM, ESPCI Paris PSL



**Dr José Dugay**  
Associate Professor  
LSABM, ESPCI Paris PSL



**Pr Benoît Piro**  
Professor of Chemistry  
& Biosensors, U. Paris Cité,  
Print'Up Institute



**Dr Bérengère Lebantal**  
Chief Engineer of Water, Bridges  
and Forests Laboratoire IMSE  
Université Gustave Eiffel.

Soutenu  
par



**GOUVERNEMENT**

Liberté  
Égalité  
Fraternité




## ACADEMIC PARTNERS



# Why Support SenseBioTek?




The First and the  
only Noninvasive  
method



Early Cancer  
Detection based  
on body odor





**SenseBioTek**  
HEALTHCARE

THANK YOU FOR  
YOUR INTEREST

**Nabil Moumane, MD**  
CEO & Founder

[an.moumane@sensebiotek.com](mailto:an.moumane@sensebiotek.com) — +33 7 88 11 58 70

<https://sensebiotek.com/>

<https://www.linkedin.com/company/sensebiotek-health-care/>



